Abstract: In some aspects, the disclosure relates to compositions and methods for detecting phosphorylation of dynamin-related protein 1 (Dip1) at position Ser-616. In some embodiments, methods described by the disclosure are useful for detecting antiplatelet agent sensitivity in a subject. In some embodiments, methods described by the disclosure are useful for detecting if a subject has been previously exposed to an antiplatelet agent.

Abstract: A system for quantitative parameter mapping using magnetic resonance (MR) image includes an input for receiving a plurality of weighted MR images of a subject and a corresponding at least one imaging parameter for the plurality of weighted MR images, and a quantitative parameter mapping neural network coupled to the input and configured to estimate at least one tissue parameter and generate at least one quantitative map for the at least one tissue parameter based on the plurality of weighted MR images of the subject and the corresponding at least one imaging parameter. The quantitative parameter mapping neural network can be trained using a set of training data utilizing at least one confounder for the quantification of the at least one tissue parameter. The system can further include a display coupled to the quantitative parameter mapping neural network to display the at least one quantitative map.

Abstract: Disclosed herein is a class of molecules termed remodilins that inhibit serum response factor (SRF). By inhibiting SRF, a number of downstream pathways can be targeted. The remodilins can be used to treat glaucoma, inhibit tumor cell growth, inhibit tumor metastasis, inhibit hypoxia-induced response, and/or reduce cellular metabolism.

Abstract: The disclosure relates to compositions comprising isolated mitochondria or combined mitochondrial agents, and methods of treating disorders using such compositions.

Abstract: Aspects of the technology described herein relate to systems and techniques for detecting one or more nucleic acids comprising a target sequence of nucleotides, the method comprising incubating molecular beacons (MBs) and a concentration of nucleic acids, each comprising a sequence of nucleotides, wherein the molecular beacons are configured to generate a fluorescence signal when bound with the target sequence, performing electrophoresis by applying voltage, and determining, using the electrophoretic mobility shift of the MBs and nucleic acids during electrophoresis, the presence of the target sequence in the concentration of nucleic acids.

Abstract: This disclosure relates to selectin inhibitors, compositions, and methods related thereto. In certain embodiments, the disclosure relates to glycopeptides that contain one or more modified amino acids conjugated to a saccharide or polysaccharide. In certain embodiments, the disclosure relates to uses of the glycopeptides as anti-inflammatory, antithrombotic, or anti-metastatic agents.

Abstract: Provided are compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, stereoisomers, tautomers, isotopically labeled derivatives, polymorphs, and prodrugs thereof, wherein X1-X4, RX, RC, RB, n, and Ring A are as defined herein. The compounds may be aryl hydrocarbon receptor agonists or partial aryl hydrocarbon receptor agonists. Also provided are pharmaceutical compositions comprising a compound of Formula (I) and methods of using such compounds for treating diseases and conditions related to the activity of an aryl hydrocarbon receptor, such as, for example, inflammatory diseases, autoimmune diseases, metabolic disorders, and proliferative diseases.

Abstract: In accordance with one aspect, a system for evaluating a health condition includes a storage containing cardiopulmonary coupling (CPC) data and heart rate data for a person for a sleep time period, one or more processors, and a memory storing instructions. When the instructions are executed by the processor(s), they cause the system to access the CPC data and the heart rate data from the storage, identify one or more time periods in the sleep time period categorized as high frequency coupling (HFC) state based on the CPC data, evaluate one or more characteristics of a portion of the heart rate data corresponding to the one or more time periods, and evaluate health condition of the person based on the one or more characteristics of the portion of the heart rate data corresponding the one or more time periods categorized as HFC state.

Abstract: Systems, devices and methods are provided for fabricating anisotropic polymer materials. According to various embodiments, a fluidic device is employed to distribute a polymer solution and a flow-confining solution in order to generate a layered flow, where the layered flow is formed such that a polymer liquid sheet is sheathed on opposing sides by flow-confining liquid sheets. The fluidic device includes first and second fluid conduits, where the first fluid conduit receives the layered flow. The second fluid conduit has a reduced height relative to the first fluid conduit, such that the layered flow is constricted as it flows through the second fluid conduit. The constriction formed by the second flow conduit causes hydrodynamic focusing, reducing the thickness of the polymer liquid sheet, and inducing molecular alignment and anisotropy within the polymer liquid sheet as it is hardened and as strain is applied during extrusion of the sheet.

Abstract: Provided are novel P-selectin inhibitors, compositions and uses thereof, and methods of making thereof.

Abstract: Provided herein are systems for determining a stretch condition of a tissue and assessing the stiffness of the tissue. Also provided herein are methods for using the systems for measuring stiffness of a tissue, assessing the effect of an agent on a tissue, and identifying subjects having a disease or disorder associated with increased or decreased stiffness of a tissue.

Abstract: The present invention relates to methods for reducing soluble P-selectin and major thrombotic events in cancer patients.

Abstract: The present disclosure provides methods for modifying gluten polypeptides to produce gluten polypeptides with a reduced inflammatory potential, as well as modified plants and compositions comprising modified gluten polypeptides with a reduced inflammatory potential.

Abstract: Methods for identifying bacterial species in biofluid samples (e.g., whole blood samples) are described. The methods rely on optical spectroscopy, and enable rapid detection and identification of bacteria directly from whole blood. Not only can LSS-based techniques detect and identify bacteria in biofluids such as whole blood, but that species-level identification can potentially be made based on a small number of bacterial cells, without the need for observing entire colonies or performing susceptibility testing. The methods may comprise illuminating the biofluid sample with input light, detecting scattered light produced by the biofluid sample in response to the illuminating, generating first data indicative of a measured scattering spectrum associated with the biofluid sample using the detected scattered light, and identifying whether at least one of the bacterial species is present in the biofluid sample using the first data.

Abstract: Magnetic cell levitation and cell monitoring systems and methods are disclosed. A method for separating a heterogeneous population of cells is performed by placing a microcapillary channel containing the heterogeneous population of cells in a magnetically-responsive medium in the disclosed levitation system and separating the cells by balancing magnetic and corrected gravitational forces on the individual cells. A levitation system is also disclosed, having a microscope on which the microcapillary channel is placed and a set of two magnets between which the microcapillary channel is placed. Additionally, a method for monitoring cellular processes in real-time using the levitation system is disclosed.

Abstract: A method for diagnosing cancer in an expanded biological tissue sample of a patient comprising providing at least one sample image of the expanded biological tissue sample; providing a computer configured to analyze the sample; analyzing, with the computer, the sample detect and segment nuclei; calculating, with the computer, molecular characteristics of those nuclei; and determining, with the computer, a diagnosis of cancer of the sample by comparing the sample with a benign normal tissue reference.

Abstract: The present disclosure generally relates, in certain embodiments, to light-based treatments. In some case, a subject having or at risk for a condition such as insomnia can be treated, e.g., with light, such as green light. Other conditions include sleep disorders such as sleep apnea and other indications. In some cases, the light that is administered to the subject may be green light, or the light may have a characteristic wavelength only in a wavelength range between 510 nm and 550 nm with a bandwidth no larger than 20 nm full-width-half-maximum. Other embodiments described herein are generally directed to systems for treating such conditions, kits for treating such conditions, or the like.

Abstract: Embodiments disclosed herein provide a general, scalable, high-throughput, and high-resolution approach for experimental dissection of regulatory regions and driver nucleotides in the context of human biology and disease. Applicants present HiDRA, a novel high-resolution global screen for transcriptional regulatory activity in accessible chromatin regions, enabling high-efficiency, high-throughput, and high-resolution inference of regulatory activity.

Abstract: This disclosure relates to PEGylated selectin inhibitors, compositions, and methods related thereto. In certain embodiments, the disclosure relates to glycopeptides that contain one or more modified amino acids conjugated to a saccharide or polysaccharide and a polyethylene glycol (PEG) moiety. In some embodiments, the disclosure relates to uses of the PEGylated glycopeptides as anti-inflammatory, anti-thrombotic, or anti-metastatic agents.

Abstract: The present invention relates to compositions comprising resolvins and their use in methods of treating cancer.